PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
Phathom Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$7.01+0.09 (+1.30%)
Close on Oct 19, 2026
- Market cap
- $587.07M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$5.95 (−45.91%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Phathom Pharmaceuticals, Inc. grew revenue 110.2% to $239.66M over the twelve months to Jun 30, 2026. Free cash flow was -$36.91M.
Revenue
$239.66M
+110.2% vs. a year earlier
Operating income
-$40.64M
TTM Q2 2026
Free cash flow
-$36.91M
TTM Q2 2026
EPS, diluted
-$1.28
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $587.07M
- P/E ratio
- –
- Price to sales
- 2.45
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -6.29%
Fundamentals
- Revenue
- $239.66M
- Net income
- -$99.07M
- EPS, diluted
- -$1.28
- Free cash flow
- -$36.91M
- Book value per share
- -$4.11
- Diluted shares
- 84M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$239.66M+110.2% YoY
Gross profit
$198.73M+100.5% YoY
Operating income
-$40.64M
Net income
-$99.07M
EPS, diluted
-$1.28
Free cash flow
-$36.91M
Reported periodTrailing twelve months